Literature DB >> 6890841

[Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol].

C Rüffer, G Zorn, E Henkel, H J Mitzkat.   

Abstract

1. When giving 100 mg allopurinol and 20 mg benzbromarone in a fixed combination we found that the oxipurinol levels differed at 0 and after 4 h from those after administration of 100 mg allopurinol; the oxipurinol clearance is increased; benzbromarone increased the glomerular filtration rate as well as the urine volume. 2. The urate serum levels are decreased under additional administration of benzbromarone, the urate clearance is increased; urate levels in serum dropped slower than under monotherapy with alloprinol and increased again within the last 12 h.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6890841

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  5 in total

1.  [Differential indications for uricosuric drugs and allopurinol].

Authors:  W Gröbner; N Zöllner
Journal:  Klin Wochenschr       Date:  1989-03-01

2.  Kinetics of allopurinol and oxipurinol after chronic oral administration. Interaction with benzbromarone.

Authors:  J N Colin; R Farinotti; G Fredj; M Tod; J P Clavel; E Vignon; F Dietlin
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 4.  A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?

Authors:  Ming-Han H Lee; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

5.  Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.

Authors:  Sophie L Stocker; Kenneth M Williams; Andrew J McLachlan; Garry G Graham; Richard O Day
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.